TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07629778: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 156 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,017,600

Rescue Site Savings

+$4,627,230

Unlock Full NCT07629778 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07629778 Rescue Dossier →